Abstract A27: Cell cycle control and drugs targeting the bioenergetics of cancer

Differences in responsiveness to chemotherapeutics among patients may be associated with multiple cell types that can be found in tumors and the circulation. Recurrent or refractory disease may result from natural selection of cells in response to therapy. To design new drugs and make better use of existing drugs differences between diseased and disease causing cells in response to a specific drug requires investigation. The Warburg Effect is characteristic of the majority of cancer cell types both in tumors and the circulation. Drugs that target the underlying biochemistry of essential bioenergetic processes unique to cancer have been shown to have activity against a broad scope of cell types and disease indications while maintaining a favorable safety profile. Recent studies have shown that CPI 613 may have concentration dependent differences in the nature of response, cell death or cell cycle arrest, when tested against H460, BXPC3 and SF539 cancer cells. Understanding the mechanisms of cell cycle arrest is an important factor in choosing other drugs to be used in combination to maximize patient benefit. Results evaluating drug effects on G2/M control proteins will be presented.Note: This abstract was not presented at the conference.Citation Format: Robert Shorr. Cell cycle control and drugs targeting the bioenergetics of cancer. [abstract]. In: Proceedings of the AACR Precision Medicine Series: Cancer Cell Cycle - Tumor Progression and Therapeutic Response; Feb 28-Mar 2, ...
Source: Molecular Cancer Research - Category: Cancer & Oncology Authors: Tags: Managing G2/M Control: Poster Presentations - Proffered Abstracts Source Type: research